Keywords
Lymphoma, Non-Hodgkin ×
Eligibility Determination ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

113 Search results.

Eligibility Lymphoma, B-Cell, Non-Hodgkin's Lymphoma NCT01724021

- 7/22/20 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of Patient Preference With Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Patients With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a; ODM derived from: https://clinicaltrials.gov/show/NCT01724021

Eligibility Indolent B-cell Non-Hodgkin's Lymphoma NCT01933516

- 5/1/20 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01933516

Eligibility Indolent Non-Hodgkin's Lymphoma NCT01500083

- 4/18/20 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Criteria, Exclusion Criteria
Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01500083

Eligibility Indolent Non-Hodgkin's Lymphoma NCT01500083

- 4/18/20 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Criteria, Exclusion Criteria
Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01500083

Eligibility Indolent Non-Hodgkin's Lymphoma NCT01500083

- 4/18/20 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Criteria, Exclusion Criteria
Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01500083

Eligibility Indolent Non-follicular NCT01929265

- 4/17/20 - 1 form, 2 itemgroups, 42 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01929265

Eligibility Indolent Non-Hodgkin Lymphoma NCT01882803

- 4/17/20 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO); ODM derived from: https://clinicaltrials.gov/show/NCT01882803

Eligibility Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas With no Available Potentially NCT02030834

- 5/24/19 - 1 form, 2 itemgroups, 23 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas; ODM derived from: https://clinicaltrials.gov/show/NCT02030834

Eligibility Non-Hodgkin Lymphoma NCT02280785

- 5/24/19 - 1 form, 2 itemgroups, 35 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
To Assess the Efficacy of Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas Other Than Anaplastic Large Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT02280785

Eligibility Non-Hodgkin's Lymphoma (NHL) NCT02071888

- 5/24/19 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Criteria, Exclusion Criteria
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT02071888

Eligibility Lymphoma, Non-Hodgkin NCT02431403

- 5/3/19 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT02431403

Eligibility Lymphoma, Non-Hodgkin NCT01996865

- 5/2/19 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.; ODM derived from: https://clinicaltrials.gov/show/NCT01996865